BackSumitomo Pharma , Ltd. Overview

Sumitomo Pharma , Ltd. Long Term Debt

Latest long-term debt for SMDPY: $120B.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$119.69B
↓ 54.49% YoYΔ $-143.29B vs prior year quarter

Peer trimmed avg / median

Loading

Sumitomo Pharma , Ltd. Long Term Debt History

Loading

Sumitomo Pharma , Ltd. vs. peers: Long Term Debt Comparison

Loading

Sumitomo Pharma , Ltd. Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Sumitomo Pharma , Ltd. (SMDPY) FAQ

Sumitomo Pharma , Ltd. posts a long-term debt of $120B as of September 2026. That compares with $260B in the prior-year period — down 54.5% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Sumitomo Pharma , Ltd.'s long-term debt was $260B. The latest reading is $120B — a 54.5% year-over-year decrease (period ending September 2026). Use the history and growth charts on this page for a longer lookback.

Long-Term Debt is one piece of Sumitomo Pharma , Ltd.'s financial statement story. At $120B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for SMDPY's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Sumitomo Pharma , Ltd.'s other metric pages and overview cover the third.